Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply

被引：0

作者：

Borque-Fernando, A. ^{[1
]}

Calleja-Hernandez, M. A. ^{[2
]}

Cozar-Olmo, J. M. ^{[3
]}

Gomez-Iturriaga, A. ^{[4
]}

Perez-Fentes, D. A. ^{[5
]}

Puente-Vazquez, J. ^{[6
]}

Rodrigo-Aliaga, M. ^{[7
]}

Unda, M. ^{[8
]}

Alvarez-Ossorio, J. L. ^{[9
]}

机构：

[1] Hosp Univ Miguel Servet, Serv Urol, IIS Aragon, Zaragoza, Aragon, Spain

[2] Hosp Univ Virgen Macarena, Serv Farm, Seville, Spain

[3] Hosp Univ Virgen de las Nieves, Serv Urol, Granada, Spain

[4] Hosp Univ Cruces, Serv Oncol Radioterap, Biocruces Bizkaia Hlth Res Insitute, Baracaldo, Bizkaia, Spain

[5] Complejo Hosp Univ Santiago, Serv Urol, Santiago De Compostela, A Coruna, Spain

[6] Hosp Clin Univ San Carlos, Serv Oncol Med, Madrid, Spain

[7] Hosp Gen Univ Castellon, Serv Urol, Castellon de La Plana, Spain

[8] Hosp Univ Basurto, Serv Urol, Bilbao, Bizkaia, Spain

[9] Hosp Univ Puerta Mar, Asociac Espanola Urol, Serv Urol, Cadiz, Spain

来源：

ACTAS UROLOGICAS ESPANOLAS | 2023年 / 47卷 / 06期

关键词：

D O I：

10.1016/j.acuro.2023.04.007

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：392 / 393

页数：2

共 7 条

[1] Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Armstrong, Andrew J.
Azad, Arun A.
Iguchi, Taro
Szmulewitz, Russell Z.
Petrylak, Daniel P.
Holzbeierlein, Jeffrey
Villers, Arnauld
Alcaraz, Antonio
Alekseev, Boris
Shore, Neal D.
Gomez-Veiga, Francisco
Rosbrook, Brad
Zohren, Fabian
Yamada, Shunsuke
Haas, Gabriel P.
Stenzl, Arnulf
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (15) : 1616 - +
[2] Borque-Fernando A, 2023, ACTAS UROL ESP, V47, P111, DOI [10.1016/j.acuro.2022.12.004, 10.1016/j.acuroe.2022.12.004]
[3] Chi KN, 2021, J CLIN ONCOL, V38
[4] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, Ian D.
Martin, Andrew J.
Stockler, Martin R.
Begbie, Stephen
Chi, Kim N.
Chowdhury, Simon
Coskinas, Xanthi
Frydenberg, Mark
Hague, Wendy E.
Horvath, Lisa G.
Joshua, Anthony M.
Lawrence, Nicola J.
Marx, Gavin
McCaffrey, John
McDermott, Ray
McJannett, Margaret
North, Scott A.
Parnis, Francis
Parulekar, Wendy
Pook, David W.
Reaume, M. Neil
Sandhu, Shahneen K.
Tan, Alvin
Tan, T. Hsiang
Thomson, Alastair
Tu, Emily
Vera-Badillo, Francisco
Williams, Scott G.
Yip, Sonia
Zhang, Alison Y.
Zielinski, Robert R.
Sweeney, Christopher J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) : 121 - 131
[5] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Fizazi, Karim
NamPhuong Tran
Fein, Luis
Matsubara, Nobuaki
Rodriguez-Antolin, Alfredo
Alekseev, Boris Y.
Ozguroglu, Mustafa
Ye, Dingwei
Feyerabend, Susan
Protheroe, Andrew
Sulur, Giri
Luna, Yesenia
Li, Susan
Mundle, Suneel
Chi, Kim N.
[J]. LANCET ONCOLOGY, 2019, 20 (05) : 686 - 700
[6] Garcia-Fumero R, 2023, Actas Urol Esp (Engl Ed), V47, P390, DOI 10.1016/j.acuroe.2023.05.004
[7] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Kyriakopoulos, Christos E.
Chen, Yu-Hui
Carducci, Michael A.
Liu, Glenn
Jarrard, David F.
Hahn, Noah M.
Shevrin, Daniel H.
Dreicer, Robert
Hussain, Maha
Eisenberger, Mario
Kohli, Manish
Plimack, Elizabeth R.
Vogelzang, Nicholas J.
Picus, Joel
Cooney, Matthew M.
Garcia, Jorge A.
DiPaola, Robert S.
Sweeney, Christopher J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) : 1080 - +

← 1 →